Pharmaceutical Executive Digital Edition - February 2010
Shire’s Second Act
Brand of the Year: Avastin
As Genentech's Avastin continues to mature and spread its branches, the company is looking for high profits on the back end.
A Sturdy Framework
Improving field force business planning requires managers to run each sales territory as if it is a self-contained business operation.
Vaccines and Value
R&D is surging, but new methods and data raise new manufacturing and regulatory challenges.
Tearing Up the Rule Book
Sales compensation practices are due for an overhaul in 2010.
Assets for Advantage
Innovation won't happen until the industry is ready to sit down and make a big change.
